Cell Therapy Manufacturing and Gene Therapy Conference, December 2-3, 2015, Sheraton Airpost Hotel, Brussels, Belgium | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Log of Password Protected Pages on the Platform

Role of the basal ganglia »

Cell Therapy Manufacturing and Gene Therapy Conference, December 2-3, 2015, Sheraton Airpost Hotel, Brussels, Belgium

September 6, 2015 by 2012pharmaceutical

Cell Therapy Manufacturing and Gene Therapy Conference, December 2-3, 2015, Sheraton Airpost Hotel, Brussels, Belgium

Reporter: Aviva Lev-Ari, PhD, RN

Exclusive Site Visit to South Brussels Biopark

AGENDA

http://www.informa-ls.com/appdata/downloads/celltherapy15/CQ3554_Cell_Therapy_and_Gene_Therapy_2.pdf

Day One Wednesday 2 December 2015

Joint PLENARY SESSION: Regulatory Updates and Recent Progress

Day Two Thursday 3 December 2015

Plenary Session: Manufacturing Genetically Modified T-Cells

SPEAKERS

Jonathan Appleby
GSK, UK

Jonathan ApplebyMDL and CSO, Rare Diseases Gene TherapyGSK, UK

Lothar Germeroth,
Juno Therapeutics GmbH

Lothar Germeroth,SVP, Managing DirectorJuno Therapeutics GmbH

Christian-Homsy
Celyad, Belgium

Christian-HomsyCEOCelyad, Belgium

Dr Anthony Davies,
Dark Horse Consulting Inc, USA

Dr Anthony Davies,President,Dark Horse Consulting Inc, USA

Ms Bernadette Keane,
Bluebird bio, USA

Ms Bernadette Keane,Vice President, Quality,Bluebird bio, USA

Dr Knut Niss,
Novartis, USA

Dr Knut Niss,Senior Technical Project Leader, Global Biopharm Operations,Novartis, USA

Dr Ohad Karnieli
Pluristem Therapeutics, Israel

Dr Ohad KarnieliVP, Development and ManufacturingPluristem Therapeutics, Israel

Christopher Bravery
Consulting on Advanced Biologicals, UK

Christopher BraveryDirectorConsulting on Advanced Biologicals, UK

Dr Harald Petry
uniQure, The Netherlands

Dr Harald PetryCSOuniQure, The Netherlands

James Miskin
Oxford Biomedica

James MiskinCTOOxford Biomedica

Robert Kotin,
Voyager Therapeutics, USA

Robert Kotin,Vice President, Production,Voyager Therapeutics, USA

Guang Qu,
Spark Therapeutics, USA

Guang Qu,Head, Process Development,Spark Therapeutics, USA

Abraham Scaria,
Sanofi-Genzyme, USA

Abraham Scaria,Senior Scientific Director, Gene Therapy/Ophthalmology,Sanofi-Genzyme, USA

Dr Matthias Hebben,
Genenthon, France

Dr Matthias Hebben,Head, Bioprocess,Genenthon, France

Posted in Conference Coverage with Social Media, Tissue Engineering | Leave a Comment

Leave a Reply Cancel reply

%d bloggers like this: